Zusammenfassung
In den vergangenen zehn Jahren ist die nichtalkoholische Fettlebererkrankung (NAFLD) vermehrt in den Fokus der klinischen Forschung gerückt. Der Begriff NAFLD beinhaltet die einfache nichtalkoholische Steatose oder Fettleber (NAFL) und die nichtalkoholische Steatohepatitis (NASH). Da die Inzidenz der NAFLD stark angestiegen ist, geht man davon aus, dass in den nächsten Jahren vor allem die NASH in vielen industrialisierten Ländern die Hauptursache für die Lebertransplantation sein wird. Weiterhin beobachtet man zunehmend, dass ein zirrhotischer Umbau der Leber direkt und ohne das Durchlaufen des Stadiums der NASH aus der NAFL entstehen kann. Schließlich erhärten sich die Hinweise, dass einerseits sowohl die NAFL als auch die NASH mit einem stark erhöhten Risiko für das Auftreten von Typ-2-Diabetes und kardiovaskulären Erkrankungen einhergeht und andererseits die NAFL und NASH Komplikationen des Diabetes darstellen. Im vorliegenden Beitrag werden aktuelle Erkenntnisse zur Prävalenz, Diagnose, Risikovorhersage und Therapie der NAFLD dargelegt und diskutiert.
Abstract
During the past 10 years nonalcoholic fatty liver disease (NAFLD) has moved more and more into the focus of attention of clinical research. The term NAFLD comprises the simple nonalcoholic steatosis or fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). As the incidence of NAFLD has dramatically increased, it is expected that during the coming years NASH in particular will become the main reason for liver transplantation in industrialized countries. In addition, it has become evident that scirrhotic liver fibrosis can develop directly from NAFL without going through the stage of NASH. Finally, there is accumulating evidence that both NAFL and NASH are strongly associated with an increased risk of type 2 diabetes and cardiovascular diseases and on the other hand that NAFL and NASH are complications of diabetes. This article addresses the current knowledge about the prevalence, diagnosis, risk prediction and treatment of NAFLD.
Literatur
Younossi ZM, Koenig AB, Abdelatif D et al (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84
Anderson EL, Howe LD, Jones HE et al (2015) The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS ONE 10:e140908
Williams CD, Stengel J, Asike MI et al (2011) Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Baillieres Clin Gastroenterol 140:124–131
Diehl AM, Day C (2017) Cause, pathogenesis, and treatment of nonalcoholic Steatohepatitis. N Engl J Med 377:2063–2072
Singh S, Allen AM, Wang Z et al (2015) Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13:643–654
McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM (2015) Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 62:1148–1155
Stefan N, Fritsche A, Schick F, Häring HU (2016) Phenotypes of prediabetes and stratification of cardiometabolic risk. Lancet Diabetes Endocrinol 4:789–798
Stefan N, Schick F, Häring HU (2017) Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metab 26:292–300
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59:1121–1140
Glen J, Floros L, Day C, Pryke R (2016) Guideline Development Group. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. BMJ 354:i4428
Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328–357
Roeb E, Steffen HM, Bantel H et al (2015) S2k Guideline non-alcoholic fatty liver disease. Z Gastroenterol 53:668–723
Paul S, Davis AM (2018) Diagnosis and management of nonalcoholic liver disease. JAMA. https://doi.org/10.1001/jama.2018.17365 (Epub ahead of print)
Stefan N, Häring HU, Cusi K (2018) Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol S2213-8587(18):30154–30152. https://doi.org/10.1016/S2213-8587 (Epub ahead of print)
Stefan N, Roden M (2018) Diabetes und Fettleber. Diabetol Stoffwechsel 13(Supplement 2):205–209
Dulai PS, Singh S, Patel J et al (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65:1557–1565
Cusi K (2016) Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia 59:1112–1120
Ratziu V (2018) A critical review of endpoints for non-cirrhotic NASH therapeutic trials. J Hepatol 68:353–361
Tilg H, Moschen AR, Roden M (2017) NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 14:32–42
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
N. Stefan gibt an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
H. Lehnert, Lübeck
C.C. Sieber, Nürnberg
Rights and permissions
About this article
Cite this article
Stefan, N. Neues zur nichtalkoholischen Steatohepatitis. Internist 60, 128–132 (2019). https://doi.org/10.1007/s00108-018-0550-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-018-0550-y
Schlüsselwörter
- Nichtalkoholische Fettlebererkrankung
- Diabetes mellitus Typ 2
- Kardiovaskuläre Erkrankungen
- Leberzirrhose
- Entzündung